A cross-sectional, observational study of 2 genotyped cohorts in Australia and UK suggested that sodium was associated with larger hypertensive effects for individuals with higher blood pressure (BP) genetic risk in pathways related to sodium and potassium biology. Both genetic risk and urinary electrolytes independently correlated with BP in the […]
The secondary analysis of a multicenter, randomized, controlled trial in China suggested that maintaining systolic blood pressure (SBP) at <130 mmHg offers additional cardiovascular benefits among young-older patients with high blood pressure. The trial enrolled 8511 young-older (60–80 years) hypertensive patients without prior stroke to compare the intensive treatment (SBP […]
A Swedish randomized, double-blind, repeated crossover trial revealed substantial heterogeneity in blood pressure (BP) response to drug therapy for high BP. There were 280 participants with grade 1 high BP at low risk for cardiovascular events (54% men; mean age, 64 years). Each participant was randomized to treatment with 4 […]
A US study showed that intensive systolic blood pressure (SBP) lowering increased hs-cTnT (high-sensitivity cardiac troponin T), mediated by reduced kidney filtration; and decreased NT-proBNP (N-terminal pro-B-type natriuretic peptide), mediated by the drop in SBP. The observed changes in hs-cTnT and NT-proBNP levels with intensive SBP lowering were associated with […]
A meta-analyses and metaregressions concluded that the beneficial effects of salt substitutes on blood pressure and clinical outcomes were consistent and might be generalizable across diverse population subgroups worldwide. The study included 21 trials and 31 949 participants, with 19 reporting effects on blood pressure and 5 reporting effects on […]
A dose‐response meta‐analysis suggested that the optimal combined intake of omega‐3 fatty acids for blood pressure (BP) lowering is likely between 2 g/d and 3 g/d. Doses above 3 g/d may be associated with additional benefits in lowering BP among high risk groups for cardiovascular diseases. The analysis included 71 randomized controlled trials […]
A US open-label, multicenter, randomized trial concluded that in pregnant women with mild chronic high blood pressure (BP), a strategy of targeting BP<140/90 mm Hg was associated with better pregnancy outcomes than a strategy of reserving treatment only for severe high BP, with no increase in the risk of small-for-gestational-age […]
A double-blind, placebo-controlled, crossover trial concluded that regular daily intake of 4 g acetaminophen increases systolic blood pressure (BP) in individuals with hypertension by ≈5 mm Hg when compared with placebo. The trial randomized 110 patients of high BP to receive 1 g acetaminophen 4× daily or matched placebo for 2 […]
A secondary analysis of a randomized blood pressure (BP) intervention trial suggested that certain BP medications could be used to prevent the development of cognitive decline. The analysis (April 2011 to July 2018) included 8685 patients of high BP 50 years or older with increased cardiovascular risk but without a […]
A Chinese multicenter, randomized, controlled trial concluded that intensive treatment with a systolic blood-pressure (SBP) target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg. Of the 8511 hypertensive […]